In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment. Click arrow to play Download TWiV 992 (19 MB .mp3, 32 min) Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Clearance of vaccine-derived poliovirus following remdesivir therapy for SARS-CoV-2 infection (Frontiers)  SARS-CoV-2 exposure in Norway rats from New York City (mBio) Clinical characteristics and outcomes of children with SARS-CoV-2 Infection in Korea (JKMS) Exhaled breath aerosol shedding of SARS-CoV-2 variants (CID) Outpatient treatment of COVID-19 and the development of Long COVID (The Lancet)  Nirmatrelvir and the risk of post-acute sequelae of COVID-19 (medRxiv) Risk of venous thromboembolism in nonhospitalized patients with COVID-19 (JAMA) Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID) Contribute to our ASTMH fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 992 Don’t crush Paxlovid (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]